Quality & Compliance

A growing number of deaths linked to pediatric medicines prompts the WHO to investigate “unacceptable” levels of APIs.

The PQRI has released new recommendations on E&Ls in parenterals.

As we transition into the endemic phase of the pandemic, companies will have to consider how their mRNA products will be housed and stored.

It’s relatively simple: Follow cGMP, keep your facilities clean, keep vermin out, and don’t sell unapproved products…

The world wasn’t ready for COVID-19. But if we learn the right lessons, next time next time we’ll do better.

We dig into the story of Lonza in China, and its new HPAPI expansion in Guangzhou

Advanced analytical technologies now offer the detailed assessments biopharma drug developers need.

How an initiative from EFPIA and a new public database on chemical substances could reduce animal experiments.

With the FDA still behind on inspections, manufacturers need to uncover their own blindspots.

An industry consortium is tackling one of pharma’s biggest drug-related challenges.